A newly released video titled Proving the value of malaria vaccines: how case-control studies can guide immunisation strategies looks at the value of case control studies.

EVI is committed to supporting a development pathway that ensures the highest scientific standards from early optimisation through to field evaluation

This comprehensive analysis brings renewed attention to placental malaria (PM), a condition that continues to threaten millions of pregnant women and newborns globally. Drawing on 50 studies conducted since 2013, the review confirms that placental malaria remains highly prevalent in malaria-endemic regions.

On 24-25 November, EVI team members convened at the Woudschoten Conference Center for a two-day retreat focused on strategic alignment, operational updates, and team cohesion. Situated in the tranquil woods near Zeist, Woudschoten offered an ideal backdrop for reflection, collaboration, and a bit of woodland adventure: including a hands-on session that tested the team’s real-time cooperation and adaptation in a fun, yet unexpected setting.

Since welcoming the first fellow in 2015, EVI has supported early- and mid-career researchers from low- and middle-income countries in developing their skills across the vaccine development spectrum.

Vaccines play a vital, but sometimes underappreciated, role in the fight against AMR.

This year, EVI’s dedication to improving maternal and neonatal health was highlighted, with a focus on the development of a placental malaria vaccine.

A two-day translational vaccinology workshop was hosted by EVI and the MRCG. The event was attended by 20 participants from MRCG and 8 from the University of Sierra Leone (USL), as part of the MMVC project.

EVI’s involvement underscored our commitment to strengthening vaccine research capacity, fostering collaboration across diverse research hubs, and sharing our expertise in trial delivery.